Breakthrough combo therapy trial offers hope for deadly eye cancer patients

NCT ID NCT05987332

Ongoing Disease control Sponsor: IDEAYA Biosciences Source: ClinicalTrials.gov ↗

Summary

This clinical trial is testing whether a new two-drug combination (IDE196 plus crizotinib) works better than current standard treatments for metastatic uveal melanoma, a rare but aggressive eye cancer that has spread. The study will enroll 420 patients who are HLA-A2 negative and haven't had prior systemic treatment for their advanced disease. Researchers will compare how long patients live without their cancer getting worse between the new combination and standard immunotherapy or chemotherapy options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AOUS Policlinico Le Scotte

Siena, 53100, Italy
Alfred Health

Melbourne, Victoria, 3168, Australia
Algemene Medische Oncologie UZ

Leuven, 3000, Belgium
BC Cancer Agency

Vancouver, British Columbia, V5Z4C2, Canada
California Pacific Medical Center (CPMC)

San Francisco, California, 94115, United States
Catalan Institute of Oncology

L'Hospitalet de Llobregat, 8908, Spain
Centre Hospitalier de l'Universite de Montreal- CHUM

Montreal, Quebec, H2X 0C1, Canada
Charité - Universitätsmedizin Berlin

Berlin, 12203, Germany
Cliniques Universitaires Saint Luc

Brussels, 1200, Belgium
Cross Cancer Institute, University of Alberta

Edmonton, Alberta, T6G 1Z2, Canada
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dermatologische Klinik, USZ Flughafen Geschoss 7 - Klinische Forschung

Zurich, 8058, Switzerland
Duke University Health System

Durham, North Carolina, 27710, United States
Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 20133, Italy
Fondazione Policlinico Gemelli IRCCS

Roma, 00168, Italy
Hadassah Medical Center

Jerusalem, 91120, Israel
Honor Health

Scottsdale, Arizona, 85258, United States
Hospital Clínico Universitario de Santiago de Compostela

Santiago de Compostela, 15706, Spain
Hospital General Universitario Valencia

Valencia, 46014, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Virgen Macarena

Seville, 41009, Spain
Houston Methodist Cancer Center

Houston, Texas, 77030, United States
Institut Curie

Paris, 75005, France
Istituto Nazionale dei Tumori Fondazione Pascale

Napoli, 80131, Italy
LUMC (Leids Universitair Medisch Centrum)

Leiden, 2333 ZA, Netherlands
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Minnesota Oncology Hematology, P.A.

Burnsville, Minnesota, 55337, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moores Cancer Center

La Jolla, California, 92093, United States
Mount Vernon Cancer Centre East & North Herts NHS Trust

Northwood, HA6 2RN, United Kingdom
NCT Heidelberg

Heidelberg, Baden-Wurttemberg, 69120, Germany
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy

Warsaw, 02-781, Poland
Northside Hospital Atlanta

Atlanta, Georgia, 30342, United States
Northwell Health

Manhasset, New York, 11030, United States
Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne w Gdańsku

Gdansk, 80-214, Poland
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Princess Alexander Hospital

Brisbane, Queensland, 4102, Australia
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth Hospital

Adelaide, Australia
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
SCRI at HealthONE

Denver, Colorado, 80218, United States
Sheba Medical Center

Ramat Gan, 52621, Israel
Sir Charles Gairdner Hospital

Perth, Washington, 6009, Australia
Texas Oncology- DFW

Dallas, Texas, 75246, United States
The Angeles Clinic and Research Institute

Los Angeles, California, 90025, United States
The Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
The Cancer and Hematology Centers

Grand Rapids, Michigan, 49546, United States
The Clatterbridge Cancer Centre NHS Foundation Trust

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
The Leon Berard Center

Lyon, France
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UCLA Medical Center

Los Angeles, California, 90024, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of California San Francisco

San Francisco, California, 94143, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
Universitätsklinikum Carl Gustav Carus Dresden

Dresden, Saxony, 1307, Germany
Universitätsklinikum Essen (AöR)

Essen, North Rhine-Westphalia, 45147, Germany
Universitätsklinikum Köln

Cologne, North Rhine-Westphalia, 50937, Germany
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Westmead Hospital

Sydney, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.

METASTATIC UVEAL MELANOMA